What AZmed Announced About Its Sixth FDA Clearance
AZmed said on 15 September 2026 that it received its sixth FDA clearance, covering AZchest for detecting and locating pneumothorax, pleural effusion, consolidation and an increased cardiothoracic ratio on frontal chest radiographs. With lung nodule detection cleared in March 2025, the company says AZchest now covers five findings per image and the wider Rayvolve suite covers eight FDA-cleared findings across musculoskeletal and chest X-rays.
Why the AZmed AZchest Clearance Matters to Radiology Buyers
Four findings on one image in a single clearance is a real widening, because each one would otherwise be a separate purchase, a separate integration and a separate set of alerts. A clearance says the FDA accepted the submission for those findings, so the useful comparison between vendors is the finding list and the scan type, not the clearance count. An increased cardiothoracic ratio is also a measurement rather than a diagnosis, and a buyer should know which of the four will actually change a report.
Where the AZmed Update Comes From
AZmed is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the AZmed AZchest Clearance
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start with the 510(k) summary and read the indications for use for each of the four findings.
- Then we would ask AZmed for the performance figures per finding, because a combined number hides the weakest one.
- We would check how the findings arrive in the reading workflow, since four new flags on every frontal chest X-ray changes a radiologist's day.